Please assess the completion status of the following clinical trial:

Trial Title: Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
-INCLUSION CRITERIA:~1. Males greater than or equal to 18 years of age with histologically confirmed adenocarcinoma of the prostate. Histology confirmation must be documented with a formal pathology report. Notes from an outside physician describing the pathologic findings (based on a prior review of the full pathology report) may be used if unable to obtain the original pathology report. This will eliminate the need for an additional invasive tissue biopsy.~2. Must have completed and recovered from all prior definitive therapy (surgery, brachytherapy, cryotherapy or radiotherapy) for the primary tumor, or other definitiveintent local therapy.~3. Stage D0 disease with documented biochemical progression documented by rising prostate specific-antigen (PSA) and no evidence of metastatic disease by physical examination, computed tomography (CT) scan or bone scan.~4. Prostate specific-antigen doubling time (PSADT) greater than or equal to 3 months and less than or equal to 15 months:~   * Patients must have greater than or equal to 3 PSA measurements over greater than or equal to 3 months.~  * The interval between PSA measurements must be greater than or equal to 4 weeks.~5. For patients following definitive radiation therapy or cryotherapy: a rise in PSA of \> 2ng/mL above the nadir (per Radiation Therapy Oncology Group (RTOG)-American Society for Therapeutic Radiology and Oncology (ASTRO) consensus criteria).~6. For patients following radical prostatectomy: 2 absolute PSA values \> 0.2ng/ml.~7. Non-castrate level of testosterone: greater than or equal to 50 ng/dL (prior antiandrogen treatment (ADT) allowed; must be greater than or equal to 6 months since last dose of ADT).~8. Performance Status: Eastern Cooperative Oncology Group (ECOG) 0-1.~9. Hemoglobin greater than or equal to 9.0 gm/dL, white blood cell (WBC) greater than or equal to 2,500/mm(3), absolute lymphocyte count (ALC) greater than or equal to 500/ mm(3), absolute neutrophil count (ANC) greater than or equal to 1,000/mm(3) platelet count greater than or equal to 75,000/mm(3), and prothrombin time (PT)/Partial thromboplastin time (PTT)PTT less than or equal to 1.5 times upper limit of normal (ULN) unless receiving clinically indicated anticoagulant therapy; serum glutamic-pyruvic transaminase (SGPT)/Serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 3 times ULN, total bilirubin less than or equal to 1.5 times ULN; creatinine less than or equal to 1.5 times ULN and estimated GFR (eGFR) greater than or equal to 60 ml/min.~10. Hepatitis B and C negative (unless the result is consistent with prior vaccination or prior infection with full recovery); human immunodeficiency virus (HIV) negative.~11. No use of investigational agents within 4 weeks of study enrollment or use of immunosuppressive or immunomodulating agents within 8 weeks of study entry.~12. No other concurrent anticancer therapy or prior prostate cancer vaccines expressing T-cell receptor alternate reading frame protein (TARP).~13. No alternative medications or nutriceuticals known to alter PSA (e.g. phytoestrogens and saw palmetto). Note: patients receiving medications for urinary symptoms such as Flomax or 5-alpha reductase inhibitors (finasteride and dutasteride) on a chronic stable dose for at least 3 months prior to study enrollment are allowed.~EXCLUSION CRITERIA:~1. Patients with an active second malignancy other than adequately treated squamous or basal cell carcinoma of the skin.~2. Patients with active infection.~3. Patients on immunosuppressive therapy including:~   - Systemic corticosteroid therapy for any reason. Patients receiving inhaled or topical corticosteroids may participate.~4. Other significant or uncontrolled medical illness. Patients with a remote history of asthma or active mild asthma may participate.~5. Patients who, in the opinion of the Principal Investigator, have significant medical or psychosocial problems that warrant exclusion

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1/Lead-in T-cell Receptor g Alternate Reading Frame Protein Dendritic Cell (DC) Vaccine Treatment (Type: EXPERIMENTAL): All patients to receive autologous multi-epitope T-cell receptor g alternate reading frame protein (TARP) DC vaccine before randomization
- 2/Active T-cell Receptor g Alternate Reading Frame Protein Dendritic Cell (DC) Vaccine Treatment (Type: EXPERIMENTAL): Autologous multi-epitope T-cell receptor g alternate reading frame protein (TARP) DC vaccine after randomization
- 3/Placebo (Type: PLACEBO_COMPARATOR): Autologous elutriated monocyte vaccine placebo after randomization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues